Roche (OTCMKTS:RHHBY) Coverage Initiated at Morgan Stanley

Equities researchers at Morgan Stanley initiated coverage on shares of Roche (OTCMKTS:RHHBY) in a research report issued on Wednesday, MarketBeat reports. The brokerage set an “equal weight” rating on the stock.

Separately, Sanford C. Bernstein raised shares of Roche to a “strong-buy” rating in a report on Thursday, January 30th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Roche has an average rating of “Hold”.

Roche Price Performance

OTCMKTS:RHHBY opened at $41.29 on Wednesday. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86. Roche has a one year low of $29.20 and a one year high of $42.43. The stock has a 50-day simple moving average of $36.85 and a 200 day simple moving average of $38.31.

Institutional Trading of Roche

Institutional investors have recently modified their holdings of the company. Brooklyn Investment Group acquired a new stake in shares of Roche during the 3rd quarter valued at $40,000. AlphaMark Advisors LLC acquired a new position in shares of Roche in the 3rd quarter valued at $149,000. IHT Wealth Management LLC purchased a new position in Roche in the 3rd quarter worth about $236,000. Verity Asset Management Inc. purchased a new stake in Roche during the third quarter valued at about $253,000. Finally, Canopy Partners LLC boosted its holdings in shares of Roche by 4.6% in the third quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after buying an additional 344 shares during the period.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.